Skip to main content

Switch Language

Spanish
English

Thrombosis Adviser

This website is intended to provide information to an international audience outside the USA and UK

I am a Healthcare Professional
I am a Patient

Thrombosis Adviser
for Healthcare Professionals
Base de conocimientos
Fundamentos
Introducción
Hemostasia
La cascada de la coagulación
Introducción
Inhibidores del factor Xa
Inhibidores directos de la trombina
Antagonistas de la vitamina K
Heparinas

Formación de trombos
Trombosis venosa
Trombosis arterial

Prevención del ictus
Ictus asociado a fibrilacion auricular
Introducción
Prevenção
Prevención del ictus asociado a la FA
Pacientes con FANV
Tratamiento anticoagulante
Tratamiento antiagregante
Anticoagulación en el control del ritmo cardíaco
Otras opciones
Pacientes con FAV
Farmacoterapia
Cirugía

Poblaciones especiales
Pacientes con FA y diabetes
Pacientes con FA sometidos a ICP
Pacientes con insuficiencia renal
Pacientes con empeoramiento de la función renal

Trombosis venosa
Introducción
Prevención
Introducción
Tratamiento anticoagulante
Otras opciones

Trombosis venosa profunda & Embolia pulmonar
Deep VT Introduction and Diagnosis
Introducción y diagnóstico
Treatment

Tratamiento
Complicaciones
VTE in Special Populations
Paediatric VTE

Cancer-Associated Thrombosis

Trombosis arterial
Síndrome coronario agudo
Introducción
Tratamiento
Prevención secundaria del SCA

Coronary Artery Disease (CAD)
Peripheral Artery Disease (PAD)

Glosario

Actualidad sobre trombosis
Thrombosis Digest
2022
ESC 2022 Congress Highlights
International Society on Thrombosis and Haemostasis (ISTH) Congress 2022 Newsletter
International Conference on Thrombosis and Hemostasis Issues in Cancer (ICTHIC) 2022
Your older patients with atrial fibrillation: Are you missing the broader picture?
EHRA 2022 Congress Highlights
Extended treatment for recurrent VTE: Protecting your patients for as long as they need
The use of NOACs in the extended management of cancer‑associated thrombosis
Protecting elderly patients with atrial fibrillation

2021
Preserving kidney function in patients with atrial fibrillation: What do the new data say?
Bayer symposium highlights from the ESC congress 2021
Protecting vulnerable patients with VTE: Choose a guideline-recommended therapy that has been thoroughly tested
Ensuring protection for patients with cancer-associated thrombosis
International Society on Thrombosis and Haemostasis Conference 2021 newsletter
Patient preference: How can it help to reduce the burden of thrombosis in patients with cancer-associated thrombosis?
Stroke prevention in older patients: How can you protect those who need it most?
International Conference on Thrombosis and Hemostasis Issues in Cancer 2021

2020
When is the right time to start thinking about renal function in patients with AF?
Thrombosis Adviser at the European Society of Cardiology Congress 2020
Extended Treatment for VTE: Tailoring Treatment for Patients Who Need it
Patients with diabetes and atrial fibrillation: How can the risk of cardiovascular death be reduced?
Manejo de la anticoagulación durante la pandemia de COVID-19
Supporting the treatment of patients with low-risk pulmonary embolism at home
The importance of real-world evidence: A look at stroke prevention in atrial fibrillation
Keeping it simple: Single drug approaches to VTE treatment
The importance of preserving kidney function in atrial fibrillation
Where next in cancer-associated thrombosis?
Time for a change? Switching anticoagulants in patients with AF or VTE
High-risk patients with atrial fibrillation: The importance of protection
Understanding the risk of VTE recurrence: Who needs extended anticoagulation?
ESC Heart and Stroke Conference: Highlights from Bayer 24–25 January 2020
Venous protection in 2019: A year in review
Stroke prevention in patients with AF in 2019: A year in review

2019
ThrombosisAdviser at the European Society of Cardiology Congress 2019
ThrombosisAdviser at the European Society of Cardiology Congress 2019: Focus on Atrial Fibrillation
PE ESC 2019 Guidelines
Paediatric patients with VTE: Protecting the most challenging population
VTE-CAT: Reducing the burden of injections
ISTH congress highlights from Bayer July 2019
Making connections: Stroke risk in patients with multiple co-morbidities
High-risk patients with atrial fibrillation: Spotlight on renal impairment
High-risk patients with atrial fibrillation: Spotlight on diabetes
VTE Treatment in Challenging Patient
Dosing Schemas of the NOACs for VTE Treatment
ESC Heart and Stroke Conference Highlights
Improving AF Detection

2018
Interpreting Safety Results of NOACs Based on Bleeding Risk
Managing the multi-morbid patient with AF: Focus on patients with renal impairment
Challenges in Interpreting Real-World Studies Involving the NOACs
Residual MACE in CAD: What Are the Long-Term Adverse Cardiac Events to Worry About?

Datos de la práctica clínica real
Introducción
Estudios de la vida real sobre la FA
Estudios de la vida real sobre el SCA
Estudios de la vida real sobre la TEV

Herramientas y recursos
¿Qué anticoagulante elegir?
Galería de imágenes
Biblioteca de audio
Galería de vídeos
Timelines
Anticoagulant Timeline
Stroke Prevention
Atrial fibrillation: A patient’s journey
OACs Timeline
Stroke Risk Evaluation Timeline

Venous Protection
Treatment of VTE Timeline
VTE: A patient’s journey

COVID-19 Paciente Liste
Vascular Adviser
for Healthcare Professionals
for Patients and Carers

Toggle Search

Toggle Search

Vascular Adviser
Patiente
Base de conocimientos
Actualidad sobre trombosis
- Thrombosis Digest
- Datos de la práctica clínica real
Herramientas y recursos
Newsletter Subscribe Form

Country select
- Country 1
- Country 2

Switch Language

Spanish
English

Thrombosis Adviser
for Healthcare Professionals

Herramientas y recursos

¿Qué anticoagulante elegir?
Galería de imágenes
Biblioteca de audio
- Tromboembolia venosa
- Prevención de accidentes cerebrovasculares en pacientes con fibrilación auricular y comorbilidades
Galería de vídeos

See Also

Peripheral Artery Disease: causes and consequences

Coronary Artery Disease: causes and consequences

Peripheral Artery Disease: causes and consequences

Peripheral Artery Disease: causes and consequences

Coronary Artery Disease: causes and consequences

Coronary Artery Disease: causes and consequences

Breadcrumb

Galería de vídeos

Video Library

Filter by Topic:

All
Atrial Fibrillation
Arterial Thrombosis
Coagulation Cascade
Coronary Artery Disease and Peripheral Artery Disease
VTE

Videos filtered by:

ESC 2020 AF Diabetes Symposium (mobile optimized version)

ESC 2020 AF Diabetes Symposium (mobile optimized version)

Manesh Patel and his colleagues on patients with AF and diabetes at the ESC congress 2020

© Bayer AG, 2020 | Approval number MA-M_RIV-ALL-0810-2

High-risk Subgroups in COMPASS, Patients with a Prior MI

High-risk Subgroups in COMPASS, Patients with a Prior MI

Ms. Anand talking about “High-risk Subgroups in COMPASS, Patients with a Prior MI”

© Bayer AG, 2020 | Approval number PP-XAR-ALL-0582-1

Trombosis venosa

Trombosis venosa

Video explicativo de la forma de actuar de la trombosis venosa

© Bayer AG, 2020 | N.º de autorización PP-XAR-ALL-1382-1

De EINSTEIN a evidencias del mundo real

De EINSTEIN a evidencias del mundo real

El programa de estudios clínicos EINSTEIN evaluó la seguridad y eficacia de rivaroxabán en comparación con AVK en pacientes con TEV

© Bayer AG, 2020 | N.º de autorización PP-XAR-ALL-0092-1

Aspirina, EINSTEIN CHOICE y tratamiento de TEV a largo plazo

Aspirina, EINSTEIN CHOICE y tratamiento de TEV a largo plazo

El profesor Paolo Prandoni analiza el papel del AAS en el tratamiento prolongado del TEV y analiza el reciente estudio EINSTEIN CHOICE, que comparó dos dosis de rivaroxabán con AAS para el tratamiento prolongado del TEV

© Bayer AG, 2020 | N.º de autorización PP-XAR-ALL-1747-1

Protección ampliada contra TEV recurrente

Protección ampliada contra TEV recurrente

Proteja a sus pacientes del TEV considerando sus factores de riesgo individuales y proporcionando una anticoagulación prolongada adecuada

© Bayer AG, 2020 | N.º de autorización PP-M_RIVALL-0086-1

Load more

Video Categories (field_video_categories)

Videos filtered by:

Videos filtered by:

See Also

Peripheral Artery Disease: causes and consequences

See Also

Coronary Artery Disease: causes and consequences

BASE DE CONOCIMIENTOS
ACTUALIDAD SOBRE TROMBOSIS
HERRAMIENTAS Y RECURSOS
THROMBOSIS ADVISER
SITEMAP

Copyright © Bayer AG |

| Updated date 10/10/2022

La finalidad de este sitio web es proporcionar información al público internacional fuera de los EE. UU. y el Reino Unido.

Pie de imprenta
Política de Privacidad
Condiciones de uso
Notificar una reacción adversa
Grupo Bayer

Copyright © Bayer AG |

Updated date 10/10/2022

La finalidad de este sitio web es proporcionar información al público

internacional fuera de los EE. UU. y el Reino Unido.

Síganos

Button

Button

Button

Button

Cookie consent image